Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

The Next Great Biotech Boom Has Arrived

Published

on

the-next-great-biotech-boom-has-arrived

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary

LONDON, March 19, 2024 /PRNewswire/ — The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in “magic mushrooms,” as a “breakthrough therapy” for the treatment of major depressive disorder three times. And the world’s largest clinical trial ever into the use of psilocybin for treating depression at London hospital in what scientists are hailing as a “milestone” in mental health research. Mentioned in today’s commentary includes:  Johnson & Johnson (NYSE: JNJ), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), Atai Life Sciences N.V. (NASDAQ: ATAI), AbbVie Inc. (NYSE: ABBV).

This new frontier in treatment has kickstarted a multi-trillion-dollar industry geared at fixing the brain through therapy.

Johnson and Johnson has gone all in on its fastest-growing drug for depression, SPRAVATO, which is the only FDA-approved psychedelic medicine on the market. In its Q4 2023 earnings released in January, JNJ reported a 74.1% increase in sales of SPRAVATO worldwide and views the drug as its next billion-plus product.

And some of the core team members behind the development of the SPRAVATO have now joined a small, but emerging NYSEAmerican-listed company, CYBIN (CYBN, CYBN.NE).

CYBIN has now been granted “Breakthrough Therapy Designation”, and is the first adjunctive psychedelic-based therapy for Major Depressive Disorder (MDD) ever to receive this FDA designation.

Oppenheimer initiated coverage on CYBN last year, saying it was encouraged by the results so far and believed the stock would have room to run further with new results. It has a price target of $4.

H.C.Wainwright & Co. took it further, with a price target of US $10.00 per share, after the recent Small Pharma acquisition.

But with impressive Phase 2 results showing remission after only two doses and a coveted FDA designation, this small company is now poised for much greater attention from investors.

Phase 2: Behind the Breakthrough Therapy Designation

Advertisement

CYBIN is developing differentiated, next-generation therapeutics that hope to offer fast, sustained therapeutic effects that are safe and tolerable, with efficacy in only 1-2 doses and short in-clinic times.

The company is on the leading edge of transformational psychedelic therapeutics, developing novel and proprietary therapeutics to improve clinical outcomes and patients’ mental health and well-being. The emerging biopharmaceutical company already has clinical validation of the novel, proprietary CYB003 molecule, which demonstrates a rapid-acting and robust psychedelic profile at a low dose. And it’s been pounding the patent pavement, too.

In August, CYBIN agreed to acquire Small Pharma Inc in an all-share transaction that creates an international clinical-stage leader in novel psychedelic therapeutics. The companies’ combined portfolios, at closing, will include two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy. The combined portfolio creates the industry’s largest, most advanced, well protected DMT program.

The combined company has the intellectual property strength of 29 patents granted and 158 patents pending in the psychedelic drug development sector. That is the largest portfolio in the industry.

Phase 2 topline efficacy data for the company’s CYBOO3 was one of the biggest drivers of value for CYBIN in the near-term, and the results were even better than expected.

Now that it’s been granted “Breakthrough Therapy Designation”, CYBIN is targeting the potential for its CYB003 to achieve “Best-in-Class Status”, and it’s confident it has a solid shot at this.

In targeting depression, CYBIN’s CYB003 is hoping to offer a lifeline to a chronic illness that victimizes some 280 million people around the world. They are also targeting what is now recognized as the leading cause of disability in the world, which costs the global economy an estimated $1 trillion in lost productivity annually.

Nowhere But Up: The Next Near-Term Catalysts

CYBIN plans to initiate its Phase 3 study of CYBOO3 in MDD in the middle of this year, with the Phase 2 study of CYB004 in Generalized Anxiety Disorder (GAD) launched on March 15.

For the Phase 2 proof-of-concept study of CYB004, CYBIN is using its proprietary DMT molecule, which was developed for the treatment of GAD, following the FDA’s clearance of its new drug application in January.

Advertisement

“We are building on foundational investigative work from our Phase 2a trial of intravenous SPL026 (DMT) which showed preliminary evidence of effectiveness treating anxiety with rapid onset of antidepressant effects and reduction in anxiety scores,” Drysdale said in a press release.

“The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses,” according to Johns Hopkins Center for Psychedelic and Consciousness Research.   This is a space where proprietary IP is absolutely essential, and Cybin now has 29 patents granted and 158 patents pending.

CYBIN (CYBN, CYBN.NE) is a clear leader in the biotech race for an alternative to the antidepressant empire, and now it has breakthrough therapy status, and is the first adjunctive therapy known to achieve this for massive depressive disorder.

Big Pharma is Racing for a Piece of the Pie

Johnson & Johnson (JNJ) is a global leader in healthcare, with a diverse portfolio that spans pharmaceuticals, medical devices, and consumer health products. Within this vast array, Janssen, its pharmaceutical branch, has made significant strides in mental health with esketamine, marketed as Spravato. This nasal spray, a derivative of the anesthetic ketamine, represents a significant breakthrough, gaining FDA approval for use in treatment-resistant depression. The approval of Spravato underscores J&J’s commitment to addressing complex mental health challenges.

AbbVie (ABBV) emerged as a standalone biopharmaceutical entity following its split from Abbott Laboratories in 2013. Focused on discovering treatments for a wide range of diseases, including rheumatoid arthritis and various cancers, AbbVie’s acquisition of Allergan expanded its reach into the burgeoning field of psychedelics for mental health. Allergan, known for its pioneering work in this area, has enriched AbbVie’s pipeline with potential psychedelic-based therapies.

Atai Life Sciences (ATAI) is at the forefront of transforming mental health care, prioritizing the development of treatments for mental health disorders. Atai’s innovative strategy encompasses a wide array of compounds, including psychedelics. The company’s collaborative approach, partnering with leading firms to accelerate the development of groundbreaking therapies, exemplifies its commitment to pioneering advancements in mental health treatment.

Compass Pathways (CMPS) is pioneering the therapeutic use of psilocybin, focusing its research efforts on addressing treatment-resistant depression. The company’s clinical trials and research initiatives are part of a larger mission to establish psilocybin therapy as a validated treatment option, highlighting the potential of psychedelics to offer profound therapeutic benefits. Compass’s dedication to rigorous scientific inquiry and ethical research practices positions it as a leader in the psychedelic research community, contributing valuable insights that could reshape mental health care.

MindMed (MNMD) tands as an innovator in the neuro-pharmaceutical industry, delving into the therapeutic potential of psychedelics for treating a range of mental health conditions. MindMed’s exploratory work with substances such as LSD, MDMA, DMT, and psilocybin is driven by a vision to unlock new treatment pathways for conditions like anxiety, depression, and addiction. Recent advancements in MindMed’s research highlight the company’s role in pioneering the use of psychedelics as therapeutic agents, underscoring the potential of these substances to revolutionize mental health care.

 ** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **

Advertisement

PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin, Inc. (“Cybin” or “Company”) to conduct investor awareness advertising and marketing. Cybin paid the Publisher two hundred and fifty thousand US dollars to produce and disseminate one article profiling the Company over a period of one week. This compensation should be viewed as a major conflict with our ability to be unbiased. 

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Cybin) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s drug pipeline, the reported scheduled release and commercialization of the Company’s drug pipeline, the ability to acquire customers and partners for the Company’s drug pipeline, and the projected growth and profit margins of the Company’s core product offerings.  Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the development and launch of the Company’s drug pipeline, competition, market saturation, market conditions, uncertain regulatory review, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

DISCLAIMER:  GlobalInvestmentDaily.com is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein.  The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Advertisement

Contact Information:

Media Contact e-mail:  [email protected]  U.S. Phone: +1(954)345-0611

View original content:https://www.prnewswire.co.uk/news-releases/the-next-great-biotech-boom-has-arrived-302092284.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Lanistar launches new gaming sites in Brazil as secures right to operate pending final approval on its licence

Published

on

lanistar-launches-new-gaming-sites-in-brazil-as-secures-right-to-operate-pending-final-approval-on-its-licence

Nexus International buys assets and IP of Lanistar as it divests its legacy business, enabling it to target multi-billion-dollar market

LONDON, Dec. 13, 2024 /PRNewswire/ — Lanistar has achieved a significant milestone by securing one of the first gaming licences awarded by the Brazilian SIGAP – Sistema de Gestão de Apostas (Bet Management System) in what is a transformative move for the business. The business now secured the right to operate in the Brazilian pending licence approval.

Two online platforms (skins) have been launched and are now live including megaposta.com as the business targets one of the fastest growing online gaming markets globally.

Gurhan Kiziloz, Founder, stated: “The global direction of gaming regulators over the last decade has been to replace grey markets with legal, regulated markets. This has been a response to the proliferation of online sports betting and the globalisation of the industry. So we are thrilled to have been able to launch pending the final approval on a licence to operate but to do so in a market which is set for huge growth.”

“Central to this was how we managed the future of the legacy business. As we prepared to enter this market, we took the decision to sell the IP and assets of Lanistar based in the UK, to Nexus International for an undisclosed sum,” continued Kiziloz.

“This cleared the way to divest of our legacy business and enables us to focus 100% on the Brazilian gaming industry. It also enabled us to reinvest the multi-million £ raised in that sale back into the new operation and ensure that we are cashflow positive from the get-go. This is without doubt the most exciting new operation I have launched to date and one that is already reaping rewards.”

Online sports betting in Brazil began in 2018, but the government did not start regulating the activity until this year. 

Brazilians spent 68.2 billion reais ($12.2 billion) in the year ending in June on gaming platforms abroad, according to an analysis by lender Itau Unibanco, based on central bank data. That would put it among the world’s top six sports betting markets.

In a drive to regulate the sector, the Normative Ordinance 827 was published in Brazil’s Official Diary of the Union on 21st May 2024, which laid out the requirements for those hoping to secure sports betting and gaming licences in Brazil. 

It kicked off an “adjustment period” in which gaming operators active in Brazil had until 31 December 2024 to comply with the regulatory framework for sports betting and iGaming. Companies’ applications submitted within 90 days of Ordinance 827’s release were prioritised for assessment.

Advertisement

Authorised operators have been granted a licence lasting five years, once a BRL30m ($5.9m) fee is paid, and able to offer gambling via three skins.

As with regulations in many other countries, companies must provide documentation proving they are legally qualified to operate in Brazil, including identification and registration forms for controlling entities. They must also submit a declaration of compliance with payments regulations, supported by certification from the Central Bank of Brazil. 

“We fully support the drive to regulate the sector and have complied with all the requirements we needed to ensure we were granted an operating licence. Regulation is good for both consumers, who enjoy better, more reliable services and betting companies, who can operate in a transparent predictable market,” concluded Kiziloz.

Notes to editors

About Lanistar

Lanistar was founded in 2019 by entrepreneur Gurhan Kiziloz, whose ambition is to build a fintech unicorn.

Using modern technology and working with industry-leading partners, the Lanistar team has successfully launched its first gaming sites in Brazil and is licensed by SIGAP – Sistema de Gestão de Apostas.

Contact
RICHARD MERRIN 
[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/lanistar-launches-new-gaming-sites-in-brazil-as-secures-right-to-operate-pending-final-approval-on-its-licence-302331474.html

Advertisement
Continue Reading

Fintech PR

Healthcare Revenue Cycle Management (RCM) Market Surges to USD 658.7 Billion by 2030, Propelled by 24% CAGR – Verified Market Reports®

Published

on

healthcare-revenue-cycle-management-(rcm)-market-surges-to-usd-658.7-billion-by-2030,-propelled-by-24%-cagr-–-verified-market-reports

Verified Market Reports®, a trusted name in market intelligence, is excited to announce the launch of its latest report, “Healthcare Revenue Cycle Management (RCM) Market – Trends, Opportunities, and Growth Forecast, 2024-2030.” This comprehensive analysis equips healthcare providers, technology vendors, and financial decision-makers with actionable insights to navigate the complexities of the RCM landscape.

LEWES, Del., Dec. 13, 2024 /PRNewswire/ — The Global Healthcare Revenue Cycle Management (RCM) Market is projected to grow at a CAGR of 24% from 2024 to 2030, according to a new report published by  Verified Market Reports®. The report reveals that the market was valued at USD 305.6 Billion in 2023 and is expected to reach USD 658.7 Billion by the end of the forecast period.  

The Healthcare Revenue Cycle Management (RCM) market is driven by the growing adoption of electronic health records (EHR) systems, increasing demand for cost-efficient healthcare services, and regulatory changes that mandate accurate billing and coding. The rise in healthcare expenditures and the shift toward value-based care models further support the market’s expansion.

Additionally, the increasing complexity of billing procedures and the need for timely reimbursements create demand for RCM solutions. However, market restraints include high implementation costs, data privacy concerns, and the complexity of integrating RCM systems with existing infrastructure. Limited skilled workforce and resistance to adopting new technologies in some regions also hinder growth.

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=570362

Browse in-depth TOC on Healthcare Revenue Cycle Management (RCM) Market

202 – Pages
126 – Tables
37 – Figures

Scope of The Report

REPORT ATTRIBUTES

DETAILS

Advertisement

STUDY PERIOD

2021-2030

BASE YEAR

2023

FORECAST PERIOD

2024-2030

HISTORICAL PERIOD

2021-2022

UNIT

Value (USD Billion)

Advertisement

KEY COMPANIES PROFILED

Epic Systems Corporation, McKesson Corporation, Cerner Corporation, General Electric, Allscripts, Quest Diagnostic, Siemens Healthcare, AdvantEdge Healthcare 

SEGMENTS COVERED

By Type, By Application, By Geography

CUSTOMIZATION SCOPE

Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope

 

Global Healthcare Revenue Cycle Management (RCM) Market Overview

Market Drivers Fueling Growth in the Healthcare Revenue Cycle Management (RCM) Market

  1. Adoption of Advanced Technologies
    The increasing implementation of advanced technologies such as Artificial Intelligence (AI), Machine Learning (ML), and automation is driving growth in the Healthcare Revenue Cycle Management (RCM) market. These technologies streamline billing processes, reduce human errors, and enhance decision-making capabilities. By automating routine tasks like coding and claim submission, healthcare providers can focus on more complex issues, resulting in faster reimbursements and improved financial performance. As healthcare organizations continue to embrace these innovations, the demand for RCM solutions is expected to rise significantly.
  2. Regulatory Compliance and Value-Based Care Models
    Stringent regulations, such as ICD-10 coding and the Affordable Care Act (ACA), are fueling the demand for RCM solutions to ensure accurate and compliant billing practices. Moreover, the shift towards value-based care, where reimbursement is tied to patient outcomes rather than volume, increases the complexity of revenue cycles. Healthcare organizations must adapt their billing systems to meet new regulatory standards and optimize their revenue through better tracking of patient care data. This need for compliance and optimization is a key driver for the growth of the RCM market.
  3. Rising Healthcare Costs and Financial Pressure
    With rising healthcare costs and an increasing volume of insurance claims, healthcare providers face greater financial pressure to streamline their revenue cycle processes. Efficient RCM systems help reduce denials, accelerate payments, and ensure more accurate coding and billing, which is critical to improving cash flow. Healthcare organizations are investing in RCM solutions to mitigate revenue loss due to billing errors, claim rejections, or delayed reimbursements. This financial imperative is a major factor driving the adoption of RCM technologies in hospitals and clinics worldwide.

To Purchase a Comprehensive Report Analysis: https://www.verifiedmarketreports.com/download-sample/?rid=570362

Market Restraints Limiting Expansion in the Healthcare Revenue Cycle Management (RCM) Market

Advertisement
  1. High Implementation Costs
    Implementing advanced healthcare revenue cycle management (RCM) systems often requires substantial upfront investment, which can be a significant deterrent for smaller healthcare providers. Expenses related to software acquisition, hardware upgrades, and training staff to use these systems effectively add to the financial burden. Many providers, particularly in rural or underserved areas, struggle to justify these costs given their limited budgets. This financial strain restricts their ability to adopt new technologies that could improve operational efficiency. Consequently, the high implementation cost remains a key restraint to the broader adoption of RCM systems.
  2. Complex Regulatory Compliance
    The healthcare industry is subject to stringent regulatory requirements, which add complexity to the revenue cycle management process. Frequent changes in healthcare policies, such as coding updates, insurance mandates, and compliance standards, demand constant monitoring and adaptation. Navigating these regulatory landscapes requires specialized knowledge and resources, which many healthcare providers lack. Non-compliance can lead to costly penalties and revenue losses, discouraging investment in RCM solutions. This challenge is particularly acute for smaller organizations, limiting their ability to scale and compete effectively in the market.
  3. Data Privacy and Security Concerns
    The handling of sensitive patient data in RCM systems raises significant concerns about data privacy and security. Cyberattacks, data breaches, and unauthorized access to patient information can have severe consequences, including legal liabilities and reputational damage. Healthcare providers must invest heavily in cybersecurity measures to safeguard their RCM platforms, further increasing operational costs. The fear of potential breaches and non-compliance with data protection regulations, such as HIPAA in the United States, deters many providers from fully embracing digital RCM solutions. These concerns act as a major restraint in the expansion of the healthcare RCM market.

Geographic Dominance

The Healthcare Revenue Cycle Management (RCM) market demonstrates remarkable geographic diversity, with North America leading due to advanced healthcare infrastructure, widespread adoption of technology, and favorable regulatory frameworks. Europe follows closely, benefiting from robust healthcare systems and increasing investments in digital health solutions. Asia is emerging as a key player, driven by rapid urbanization, expanding healthcare services, and the growing need for efficient billing and coding processes in densely populated countries like China and India. Meanwhile, Africa and other emerging regions are showing significant potential, fueled by improving healthcare infrastructure and initiatives aimed at modernizing financial systems in healthcare.

As global demand for cost-effective and efficient healthcare services grows, these regions are expected to experience accelerated adoption of RCM solutions. Technological advancements and the increasing prevalence of value-based care models are further driving growth across these geographies. Additionally, partnerships between global and local firms are fostering innovation and market penetration. This geographic spread highlights the dynamic nature of the RCM market and its potential for sustained expansion worldwide.

Healthcare Revenue Cycle Management (RCM) Market Key Players Shaping the Future

Major players, including Epic Systems Corporation, McKesson Corporation, Cerner Corporation, General Electric, Allscripts, Quest Diagnostic, Siemens Healthcare, AdvantEdge Healthcare, CareCloud, Acelerartech and more, play a pivotal role in shaping the future of the Healthcare Revenue Cycle Management (RCM) Market. Financial statements, product benchmarking, and SWOT analysis provide valuable insights into the industry’s key players.

Healthcare Revenue Cycle Management (RCM) Market Segment Analysis

Based on the research, Verified Market Reports® has segmented the global Healthcare Revenue Cycle Management (RCM) Market into Type, Application and Geography.

  • Healthcare Revenue Cycle Management (RCM) Market, By Type
    • On-Premises
    • Cloud-Based
  • Healthcare Revenue Cycle Management (RCM) Market, By Application
    • Hospitals
    • Ambulatory Services
  • Healthcare Revenue Cycle Management (RCM) Market, By Geography
    • North America
      • U.S
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia Pacific
    • ROW
      • Middle East & Africa
      • Latin America

Browse Related Reports:

Global Healthcare Revenue Cycle Management (RCM) Software Market By Type (Cloud-based, On-premise), By Application (Hospitals, Physician), By Geographic Scope And Forecast

Global Healthcare RCM Outsourcing Market By Type (Pre-intervention, Intervention), By Application (Small/Rural Hospitals, Community Hospitals), By Geographic Scope And Forecast

Global Medical Billing Service Market By Type (On-premise, Cloud Based), By Application (Clinical, Operations), By Geographic Scope And Forecast

Global Medical Patient Financing Market By Type (Equipment and Technology Finance, Working Capital Finance), By Application (Hospitals & Health Systems, Outpatient Imaging Centers), By Geographic Scope And Forecast

Advertisement

Global Healthcare Marketing Services Market By Type (Branding, Reputation Management), By Application (Hospitals, Pharmaceutical Companies), By Geographic Scope And Forecast

About Us

Verified Market Reports® ­stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, Verified Market Reports has been instrumental in providing founders and companies with precise, up-to-date research data.

With a team of 500+ Analysts and subject matter experts, Verified Market Reports leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.

Verified Market Reports’ domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.

Verified Market Reports® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights Verified Market Reports’ dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.

Contact Us
Mr. Edwyne Fernandes
Verified Market Reports®
US: +1 (650)-781-4080
US Toll Free: +1 (800)-782-1768
Email: [email protected]
Web: https://www.verifiedmarketreports.com/
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/2486715/VM_Reports.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/healthcare-revenue-cycle-management-rcm-market-surges-to-usd-658-7-billion-by-2030–propelled-by-24-cagr—verified-market-reports-302331334.html

Continue Reading

Fintech PR

Causal AI Market worth $456.8 million by 2030- Exclusive Report by MarketsandMarkets™

Published

on

causal-ai-market-worth-$456.8-million-by-2030-exclusive-report-by-marketsandmarkets

DELRAY BEACH, Fla., Dec. 13, 2024 /PRNewswire/ — The Causal AI Market is slated to expand from USD 56.2 million in 2024 to USD 456.8 million by the year 2030 at an impressive CAGR of 41.8% over the forecast period, according to a new report by MarketsandMarkets™. 

Browse in-depth TOC on “Causal AI Market”

330 – Tables
54 – Figures
331 – Pages

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162494083

Scope of the Report

Report Metrics

Details

Market size available for years

2019–2030

Base year considered

Advertisement

2023

Forecast period

2024–2030

Forecast units

USD (Million)

Segments covered

Offering, Application, Vertical and Region

Geographies covered

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America

Companies covered

Advertisement

IBM (US), Google (US), Microsoft (US), Dynatrace (US), Cognizant (US), Logility (US), Datarobot (US), CausaLens (UK), Aitia (US), Taskade (US), Causely (US), Causaly (UK), Causality Link (US), Xplain data (Germany), Parabole.AI (US), Datma (US), Incrmntl (Israel), Scalnyx (France), Geminos (US), Data Poem (US), CausaAI (Netherlands), Causa (UK), Lifesight (US), Actable AI (UK), biotx.ai (Germany), Howso (US), VELDT (Japan), and CML Insight (US)

The Causal AI Market is witnessing sharp expansion as it can address important issues that traditional AI finds difficult to resolve. This need for transparency, trust, and actionable insights is driving the adoption of causal AI. The adoption of causal AI is being driven by the demand for transparency, trust, and actionable insights in critical sectors such as healthcare, finance, and supply chain management. Causal AI is an essential tool for companies wanting to remain competitive in a data-driven world, as it can reveal cause-and-effect relationships and improve decision-making. For example, companies are using causal AI to comprehend the real factors behind customer behavior, improve marketing tactics, or forecast the consequences of operational choices. Moreover, improvements in data accessibility, computing capabilities, and user-friendly interfaces are reducing obstacles for organizations of all sizes to adopt causal AI solutions.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=162494083

By offering, causal inference tools segment will register the fastest growth rate over the forecast period owing to enhanced decision making across diverse scenarios

Causal inference tools are becoming the most rapidly expanding segment in the Causal AI Market because of their adaptability and availability in various industries. These tools give organizations the ability to discover cause-and-effect relationships within their data, allowing for accurate decision-making in fields such as marketing, healthcare, and operations. Businesses are starting to realize the drawbacks of AI that relies on correlations, as it only detects patterns without providing explanations for outcomes. Causal inference tools help to close this divide by providing useful information that can be used to shape strategies, like determining which marketing campaigns increase customer engagement or studying the factors that impact patient recovery. Their growth is also fueled by the availability of intuitive, user-friendly interfaces that allow non-technical users to apply complex causal analysis without requiring deep expertise. Causal inference tools are becoming essential as organizations require more accountability and transparency in their decision-making, leading to their quick adoption.

Rising adoption of causal AI to augment financial decision making with cause-and-effect analysis will push BFSI as the largest vertical by market size in 2024

The BFSI vertical is poised to hold the largest market share in the Causal AI Market, fueled by its requirements for clarity, risk control, and practical information. Causal AI helps financial institutions tackle ever-changing, regulated environments where comprehending the reasons behind events is just as important as foreseeing them. For instance, JPMorgan Chase utilizes causal AI to pinpoint the underlying reasons for customer turnover, enabling specific actions to keep valuable customers. In the same way, Citibank employs causal models to evaluate the effects of different credit risk strategies, leading to enhanced loan approval procedures and a decrease in defaults. In the insurance industry, firms such as Allstate have implemented causal AI to enhance the identification of claim fraud by pinpointing actions that are closely linked to fraudulent behavior, resulting in a documented decrease of over 10% in unnoticed fraud. In addition, insurance companies employ causal AI to customize policy suggestions by examining the specific reasons for customer preferences, greatly improving customer contentment. Compliance with regulations continues to drive the increase in adoption. For example, HSBC uses causal AI to comply with AML laws by identifying causal connections in transaction data, simplifying investigations, and avoiding significant penalties. The use of causal AI in precise decision-making, along with its demonstrated effects on profitability and compliance, cements BFSI as the top vertical in the market.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162494083

Asia Pacific is set to become the fastest growing region over the forecast period, fueled by increasing investments in responsible AI deployment for decision-making

Several key factors are driving rapid growth in the Causal AI Market in the Asia Pacific. Governments and businesses in the APAC region, specifically in nations such as China, Japan, and India, are making significant investments in AI innovation to promote the development and utilization of causal AI technologies. Sectors like healthcare and finance in the region are utilizing causal AI to enhance decision-making and operational efficiency. Hospitals in Singapore are using causal AI in healthcare to enhance treatment plans, leading to a substantial enhancement in patient results. Banks in India are using causal AI in the financial industry to improve fraud detection, leading to a significant decrease in fraudulent transactions. Manufacturing hubs in countries like Vietnam and Thailand are adopting causal AI to predict and mitigate disruptions. This trend is also assisted by the regional regulatory landscape, which favors responsible artificial intelligence practices, increasing the market demand for causal models that are both transparent and free from bias.

Advertisement

Top Key Companies in Causal AI Market:

The major players in the Causal AI Market include IBM (US), Logility (US), CausaLens (UK), Aitia (US), Causely (US), Geminos (US), along with SMEs and startups such as Data Poem (US), CausaAI (Netherlands), Causa (UK), Lifesight (US), amd Actable AI (UK).

Browse Adjacent Markets: Artificial Intelligence (AI) Market Research Reports & Consulting

Related Reports:

Emotion AI Market – Global Forecast to 2030

Edge AI Software Market – Global Forecast to 2030

AI Training Dataset Market– Global Forecast to 2029

AI Agents Market– Global Forecast to 2030

AI as a Service Market– Global Forecast to 2029

Get access to the latest updates on Causal AI Companies and Causal AI Industry

Advertisement

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/causal-ai-market-worth-456-8-million-by-2030–exclusive-report-by-marketsandmarkets-302331128.html

Advertisement
Continue Reading

Trending